Pharmacokinetics of bevacizumab in haemodialysis.
Garnier-Viougeat
Nathalie
N
Rixe
Olivier
O
Paintaud
Gilles
G
Ternant
David
D
Degenne
Danielle
D
Mouawad
Roger
R
Deray
Gilbert
G
Izzedine
Hassane
H
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015314:Dialysis Solutions / Q000737:chemistry*; D029721:Drosophila Proteins; D004797:Enzyme-Linked Immunosorbent Assay; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D011956:Receptors, Cell Surface; D006435:Renal Dialysis / Q000379:methods*; D051437:Renal Insufficiency / Q000378:metabolism* / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015314:Dialysis Solutions; D029721:Drosophila Proteins; D011956:Receptors, Cell Surface; D042461:Vascular Endothelial Growth Factor A; C405956:gustatory receptor, Drosophila; D000068258:Bevacizumab